129 related articles for article (PubMed ID: 30173784)
1. Central retinal vein occlusion associated with vemurafenib use in metastatic skin melanoma.
Yang SY; Chen SN
Kaohsiung J Med Sci; 2018 Sep; 34(9):535-536. PubMed ID: 30173784
[No Abstract] [Full Text] [Related]
2. Drug reaction with eosinophilia and systemic symptoms syndrome induced by combination of vemurafenib and cobimetinib in melanoma: A series of 11 cases.
Brégeon B; Bernier C; Josselin N; Peuvrel L; Le Moigne M; Saint-Jean M; Quéreux G
J Am Acad Dermatol; 2019 Feb; 80(2):558-562. PubMed ID: 30081108
[No Abstract] [Full Text] [Related]
3. Vemurafenib-induced plantar hyperkeratosis.
Bashline BR; Bedocs PM
Cutis; 2018 Sep; 102(3):E19-E21. PubMed ID: 30372722
[No Abstract] [Full Text] [Related]
4. Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma.
Eser Öztürk H; Süllü Y
Turk J Ophthalmol; 2020 Mar; 50(1):50-52. PubMed ID: 32167264
[TBL] [Abstract][Full Text] [Related]
5. Toxic epidermal necrolysis induced by vemurafenib after nivolumab failure.
Arenbergerova M; Mrazova I; Horazdovsky J; Sticova E; Fialova A; Arenberger P
J Eur Acad Dermatol Venereol; 2017 May; 31(5):e253-e254. PubMed ID: 27739125
[No Abstract] [Full Text] [Related]
6. [Severe panuveitis in a metastatic cutaneous melanoma patient treated with vemurafenib].
Boiché M; Conart JB; Angioi-Duprez K
J Fr Ophtalmol; 2018 Jun; 41(6):e291-e292. PubMed ID: 29908650
[No Abstract] [Full Text] [Related]
7. Partial response of metastatic melanoma to BRAF-inhibitor-monotherapy in a pregnant patient with no fetal toxicity.
Marcé D; Cornillier H; Denis C; Jonville-Bera AP; Machet L
Melanoma Res; 2019 Aug; 29(4):446-447. PubMed ID: 31246727
[No Abstract] [Full Text] [Related]
8. A Rare Cause of Uveitis: Vemurafenib.
Sızmaz S; Görkemli N; Esen E; Demircan N
Turk J Ophthalmol; 2018 Dec; 48(6):323-325. PubMed ID: 30605942
[TBL] [Abstract][Full Text] [Related]
9. Rechallenge With Nivolumab After Vemurafenib Treatment of Initially Nivolumab-Resistant Advanced Melanoma.
Kato J; Hida T; Kamiya T; Sato S; Takahashi H; Torigoe T; Uhara H
JAMA Dermatol; 2018 May; 154(5):621-622. PubMed ID: 29590278
[No Abstract] [Full Text] [Related]
10. Acantholytic dyskeratotic acanthoma: a possible skin adverse event of vemurafenib treatment.
Komori T; Otsuka A; Kaku Y; Honda T; Kabashima K
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):e474-e475. PubMed ID: 28426905
[No Abstract] [Full Text] [Related]
11. A Case of Perforating Folliculitis Induced by Vemurafenib.
Shiraishi K; Masunaga T; Tohyama M; Sayama K
Acta Derm Venereol; 2019 Feb; 99(2):230-231. PubMed ID: 30281138
[No Abstract] [Full Text] [Related]
12. Decreased photosensitivity to UVA on vemurafenib combined with cobimetinib.
Frenard C; Dutartre H; Boisrobert A; Khammari A; Dreno B
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):e87-e88. PubMed ID: 30198584
[No Abstract] [Full Text] [Related]
13. Case of severe acneiform eruptions associated with the BRAF inhibitor vemurafenib.
Ansai O; Fujikawa H; Shimomura Y; Abe R
J Dermatol; 2017 Mar; 44(3):e15-e16. PubMed ID: 27511106
[No Abstract] [Full Text] [Related]
14. Two cases of successful treatment for severe skin rash induced by vemurafenib following nivolumab therapy without cessation of vemurafenib.
Tsuboi S; Yoshino K; Yamaguchi K; Imafuku K; Ohara K
J Dermatol; 2017 May; 44(5):607-608. PubMed ID: 27334634
[No Abstract] [Full Text] [Related]
15. Neutrophilic panniculitis with vasculitis in a melanoma patient treated with vemurafenib: a case report and its management.
Ueno M; Namiki T; Inui K; Hanafusa T; Miura K; Yokozeki H
Int J Dermatol; 2017 Aug; 56(8):e163-e165. PubMed ID: 28244062
[No Abstract] [Full Text] [Related]
16. Keratoacanthoma, palmoplantar keratoderma developing in an advanced melanoma patient treated with vemurafenib regressed by blockade of mitogen-activated protein kinase kinase signaling.
Furudate S; Fujimura T; Kambayashi Y; Hidaka T; Sato Y; Tanita K; Hashimoto A; Aiba S
J Dermatol; 2017 Sep; 44(9):e226-e227. PubMed ID: 28439948
[No Abstract] [Full Text] [Related]
17. Systematic review and meta-analysis of prevalence of dermatological toxicities associated with vemurafenib treatment in patients with melanoma.
Chen P; Chen F; Zhou B
Clin Exp Dermatol; 2019 Apr; 44(3):243-251. PubMed ID: 30280426
[TBL] [Abstract][Full Text] [Related]
18. RASopathic comedone-like or cystic lesions induced by vemurafenib: a model of skin lesions similar but not identical to those induced by dioxins MADISH.
Kaya G; Saxer-Sekulic N; Kaya A; Sorg O; Boespflug A; Thomas L; Saurat JH
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1368-1372. PubMed ID: 29575357
[TBL] [Abstract][Full Text] [Related]
19. Facial spiny follicular hyperkeratosis induced by vemurafenib.
Nieto Rodríguez D; Gómez Fernández C; Rueda Carnero JM
J Dermatol; 2018 Feb; 45(2):e43-e44. PubMed ID: 28971523
[No Abstract] [Full Text] [Related]
20. Nivolumab therapy before vemurafenib administration induces a severe skin rash.
Imafuku K; Yoshino K; Ymaguchi K; Tsuboi S; Ohara K; Hata H
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):e169-e171. PubMed ID: 27546003
[No Abstract] [Full Text] [Related]
[Next] [New Search]
